U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07848295) titled 'A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)' on Sept. 22.
Brief Summary: The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)
Study Start Date: Dec. 31
Study Type: INTERVENTIONAL
Condition:
Clear Cell Renal Cell Carcinoma (ccRCC)
Intervention:
DRUG: BMS-986527
Specified dose on specified days
DRUG: Nivolumab
Specified dose on specified days
DRUG: Cabozantinib
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Juno Therapeutics, ...